Cancer Research Annual Meeting 2010  2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willhauck, M.
Right arrow Articles by Keilholz, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willhauck, M.
Right arrow Articles by Keilholz, U.
[Cancer Research 63, 3483-3485, July 1, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

Restricted T-Cell Receptor Repertoire in Melanoma Metastases Regressing after Cytokine Therapy1

Martina Willhauck, Carmen Scheibenbogen, Michael Pawlita, Thomas Möhler, Eckhard Thiel and Ulrich Keilholz2

Medizinische Klinik und Poliklinik V, Hospitalstrasse 3 [M. W., T. M.] and Research Program Applied Tumor Virology, Deutsches Krebsforschungszentrum [M. P.], 69115 Heidelberg, and Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitätsklinikum Benjamin-Franklin, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin [C. S., E. T., U. K.], Germany

One major rationale for using interleukin-2 and IFN-{alpha} in cancer immunotherapy is to activate tumor-specific T cells at the tumor site. To study the in situ T-cell response, we determined the T-cell receptor (TCR) repertoire in six melanoma metastases regressing after cytokine treatment obtained from five patients. Sequence analysis of overexpressed TCR ß-chain variable regions revealed the presence of clonally expanded T cells and also of T cells with highly homologous complementarity determining regions 3 in all five patients. This finding indicates that the T-cell response in regressing melanoma lesions is dominated by T cells directed toward a limited number of epitopes and that epitope-specific T cells frequently use a highly restricted TCR repertoire.




This article has been cited by other articles:


Home page
J. Immunol.Home page
J. Zhou, M. E. Dudley, S. A. Rosenberg, and P. F. Robbins
Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma
J. Immunol., December 15, 2004; 173(12): 7622 - 7629.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.